Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions.
The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should favor using drug-eluting stents.
Get the full story at our sister site, Drug Delivery Business News.
The post European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds appeared first on MassDevice.